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Transfer hydrogenation of C=O and C=N bonds is one 
of the cornerstones of synthetic organic methodology. In 
this context and thanks to their remarkable stability 
against air and water, d6-piano stool complexes of Ru, 
Rh, and Ir have found wide applications as homogene-
ous catalysts both in organic solvents and in aqueous 
media. Most frequently, either formic acid or 2-propanol 
are used as hydride source.  
Recently, the d6-piano stool-catalyzed transfer hydro-
genation has found its way in a biological context for the 
regeneration of the NAD(P)+/NAD(P)H couple. Indeed 
and in view of its use as cofactor in over 400 redox en-
zymes, the non-enzymatic regeneration of NADH by d6-
pianstool complexes has attracted significant interest in 
the past thirty years. In a biomimetic spirit, the use of 
NADH as hydride source for the generation a {Cp*M–
H}-moiety (Cp* = η5–C5Me5–) has been also achieved. 
In stark contrast to enzymes, homogeneous catalysts 
very rarely can catalyze both the forward and the reverse 
transformations. Careful design of d6-piano stool com-
plexes now allows to use NADH for the reduction of 
dioxygen, quinones, imines and aldehydes both in vitro 
and in vivo (Scheme 1). 
Transfer hydrogenation using intracellular NADH was 
utilized to promote anticancer activity. The group of 
Sadler demonstrated that Ir A (Scheme 1a) catalyzes the 
transfer hydrogenation of molecular oxygen to produce 
hydrogen peroxide using NADH as reductant (reaction i, 
Scheme 1b).1 Hydrogen peroxide is one of the reactive 
oxygen species (ROS), which causes oxidative stress. 
The Ir A complex catalyzed the production of hydrogen 
peroxide, thus displaying anticancer activity, which 
proved to be higher than that of cisplatin. 
In a related context, the group of Komatsu and Ariga 
demonstrated intracellular NADH imaging relying on its 
use as hydride source to quench the fluorescence of a 
reporter probe. They showed that Ir B (Scheme 1a) 
could use NADH as hydride source for the transfer hy-
drogenation of an ubiquinone moiety in a rhodol deriva-
tive (UQ-Rh 1) (reaction ii, Scheme 1b).2 The fluores-
cence of UQ-Rh 1 decreases upon reduction of the UQ 
moiety. Addition of Ir B to Hela cells treated by UQ-Rh 
1 resulted in fluorescence decrease, indicating that Ir B 
is able to catalyze transfer hydrogenation using NADH 
in the Hela cells. Accordingly, imaging of NADH was 
successfully demonstrated, albeit relying on a turn-off 
fluorescent probe.  
With synthetic biology applications in mind, transfer 
hydrogenation was implemented to multienzymatic cas-
cades. The group of Ward constructed an NAD(P)H-
dependent artificial transfer hydrogenase (ATHase) by 
incorporation of Ir C into streptavidin relying on the 
biotin-(strept)avidin technology (Scheme 1a).3 This 
artificial/natural enzymatic cascades performed asym-
metric imine reduction and worked at intracellular 
NAD(P)H concentrations (reaction iii, Scheme 1b).  
Despite the few examples highlighted above, the use 
of organometallic complexes as catalysts in vivo remains 
challenging. This can be traced back to the numerous 
metabolites and enzymes that may bind with high affini-
ty to d6-piano stool complexes, thus inhibiting catalysis. 
To overcome this challenge, the group of Do screened 
and identified organometallic complexes that are stable 
in the presence of various biomolecules and can use 
NADH as hydride source. They selected the reduction of 
aldehydes as catalytic transformation. Indeed, aldehydes 
derived from lipid peroxidation have been implicated in 
various diseases: reduction of these aldehydes to the 
corresponding alcohols may lead to detoxification. 
Screening of bidentate ligands, lead to the identification 
of complex Ir D (Scheme 1a) that could reduce cytotoxic 
aldehydes with NADH (reaction iv, Scheme 1b).4 Grati-
fyingly, Ir D remained active in cell culture media and 
even in the presence of biological nucleophiles, high-
lighting the high tolerance of Ir D to physiological con-
ditions. 
This achievement prompted them to test Ir D for intra-
cellular transfer hydrogenation.5 As reporter, they se-
lected a turn-on fluorescent probe. They prepared vari-
ous fluorophores bearing an aldehyde moiety as sub-
strate for transfer hydrogenation. Among substrates 
tested, Bodipy-modified with an aldehyde group (Bod-
ipy-CHO 7) was identified as a suitable substrate. Its 
reduced form, Bodipy-OH 8, displays a fivefold higher 
emission than Bodipy-CHO 7. For the in vitro experi-
ment, a twofold increase in fluorescence emission was 
 observed after 4 h upon reduction of Bodipy-CHO 7 
(reaction v, Scheme 1b).  
Next, they tested transfer hydrogenation of Bodipy-
CHO 7 in vivo. For this purpose, the NIH-3T3 mouse 
embryo fibroblast cells were selected. After incubation 
with Bodipy-CHO 7, cells were washed and treated with 
Ir D. Compared with a control experiment lacking Ir D, 
a 1.6-fold higher fluorescence of the cells was observed 
after 2h. This result suggests that transfer hydrogenation 
by Ir D occurs thanks to the presence of intracellular 
NADH as a hydride source. Ir D also catalyzes this reac-
tion in A549 human epithelial cancer cells. Importantly, 
the intracellular concentration of Ir D was quantified by 
ICP-MS. 
To ensure that intracellular NADH is indeed the hy-
dride source they modulated the intracellular NADH 
level in cells. Addition of sodium pyruvate, a natural 
metabolite that signals the slowdown of glycolysis lead-
ing to lower NADH levels, resulted in lower fluores-
cence caused by Bodipy-OH 8.    
As Do et al. demonstrated, despite the marked affinity 
of soft precious metals for various metabolites, most 
notably thiols and thioethers, careful identification of 
suitable bidentate ligands for the {Cp*Ir}-moiety, allows 
to carry out transfer hydrogenation in vivo using NADH 
as hydride source. These findings open fascinating per-
spectives for the catalytic uncaging of drugs by organo-
metallic complexes in vivo via transfer hydrogenation. 
To achieve this feat however, further efforts are required 
to improve the catalytic performance (i.e. turnover num-
bers and saturation kinetic parameters).  
 
 
Scheme 1. Various d6-pianostool iridium complexes 
(a) catalyze transfer hydrogenation reactions using 
NADH as hydride source (b). 
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